NASDAQ : LEXX
Lexaria Bioscience Corp. — Key statistics
Healthcare · Biotechnology · Canada
Last price 3.49 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 7.35M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 7.35M |
| Enterprise Value | 3.82M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 27, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 2.11M |
| Shares Outstanding | 2.11M |
| Shares Change (YoY) | +32.40% |
| Shares Change (QoQ) | +1.48% |
| Owned by Insiders (%) | 1.31% |
| Owned by Institutions (%) | 5.09% |
| Float | 2.06M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 37.90 |
| Forward PS | n/a |
| PB Ratio | 1.22 |
| P/TBV Ratio | 1.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 19.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 10.60 |
| Quick Ratio | 9.56 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -162.77% |
| Return on Assets (ROA) | -81.30% |
| Return on Invested Capital (ROIC) | -96.43% |
| Return on Capital Employed (ROCE) | -170.40% |
| Weighted Average Cost of Capital (WACC) | 7.47% |
| Revenue Per Employee | $27,714 |
| Profits Per Employee | -$1.10M |
| Employee Count | 7 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 4,403 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.60 |
| 52-Week Price Change | -75.74% |
| 50-Day Moving Average | 5.27 |
| 200-Day Moving Average | 8.96 |
| Relative Strength Index (RSI) | 48.65 |
| Average Volume (20 Days) | 59,690 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 255,776 |
| Short Previous Month | 274,542 |
| Short % of Shares Out | 12.14% |
| Short % of Float | 12.44% |
| Short Ratio (days to cover) | 3.34 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 194,000 |
| Gross Profit | 194,000 |
| Operating Income | -7.49M |
| Pretax Income | -7.74M |
| Net Income | -7.73M |
| EBITDA | -7.42M |
| EBIT | -7.49M |
| Loss Per Share | -$5.14 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 3.62M |
| Total Debt | 86,714 |
| Net Cash | 3.53M |
| Net Cash Per Share | $1.68 |
| Equity (Book Value) | 4.34M |
| Book Value Per Share | 2.87 |
| Working Capital | 3.68M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -7.43M |
| Capital Expenditures | -40,817 |
| Depreciation & Amortization | 76,573 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.47M |
| FCF Per Share | -$3.54 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -3,862.94% |
| Pretax Margin | -3,987.65% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -32.40% |
| Shareholder Yield | -32.40% |
| Earnings Yield | -147.36% |
| FCF Yield | -101.56% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 30.95% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 3, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.43 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |